Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0NLPAH
ADC Name	Glypican 3 ADC
Synonyms	A2-tub; Glypican 3 antibody drug conjugate (Bristol-Myers Squibb); Glypican 3 antibody drug conjugate; Glypican-3 ADC; Glypican3 ADC Click to Show/Hide
Organization	Bristol Myers Squibb Co.
Drug Status	Terminated in phase 1
Indication	In total 1 Indication(s) Hepatocellular carcinoma [ICD11:2C12] Terminated in phase 1
Drug-to-Antibody Ratio	1
	3D MOL	2D MOL
Antibody Name	Adnectins scaffold protein		Antibody Info
Antigen Name	Glypican-3 (GPC3)		Antigen Info
Payload Name	Tubulysin analog Tub		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Mal-EBE-Mal		Linker Info
Conjugate Type	Site-specific conjugation through the engineered C-terminal cysteine

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	100	%	Hep 3B2.1-7 cells	Childhood hepatocellular carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Positive GPC3 expression (GPC3+++/++)
Method Description	Female NOD/SCID mice were inoculated subcutaneously in the right flank with 500,000 Hep3B cells. Three weekly administration of A2-tub at 0.12 mol/kg.
In Vivo Model	Hep3B CDX model
In Vitro Model	Childhood hepatocellular carcinoma	Hep 3B2.1-7 cells		CVCL_0326

References

Ref 1	Adnectin-drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. Protein Eng Des Sel. 2018 May 1;31(5):159-171. doi: 10.1093/protein/gzy013.